MWN105 / Minwei Biotech - LARVOL DELTA

MWN105—A Next-Generation GLP-1/GIP/FGF21 Agonist for the Treatment of NASH (ADA 2025) - "The study assessed liver histology, metabolic biomarkers, body weight, and enzyme activity compared to tirzepatide. In the B6-Alms1-del NASH mouse model, MWN105 significantly reduced body weight, liver weight, and liver-to-body weight ratio. MWN105 demonstrates potent metabolic and antifibrotic effects, addressing key NASH pathologies. MWN105 has a potential best-in-class therapeutic profile for NASH. MWN105 has obtained IND clearance in both the U.S. and China and Further Phase I clinical study is on-going."

Late-breaking abstract • Diabetes • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • FGF21